Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2007-000964-26Phase 2Completed
Phase 2, open-label, single-arm trial of Fluzone Trivalent in influenza, sponsored by Novartis. Primary endpoints: Immunogenicity by single radial hemolysis and Safety after single intramuscular FLUAD dose. Started Jun 2007; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on 2007-000964-26.